2016
DOI: 10.1210/jc.2016-2217
|View full text |Cite
|
Sign up to set email alerts
|

ω-3 Fatty Acid Ethyl Esters Diminish Postprandial Lipemia in Familial Hypercholesterolemia

Abstract: Supplementation with ω-3 FAEEs improves postprandial lipemia in FH patients receiving standard care; this may have implications for further reducing atherosclerotic cardiovascular disease in this high-risk patient group.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
51
2
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 32 publications
(56 citation statements)
references
References 34 publications
2
51
2
1
Order By: Relevance
“…[9,11,14,[16][17][18][19] Among the rest studies including adults with FH, in 8 RCTs the subjects were also treated with lipid-lowering drugs. [10,13,15,[20][21][22][23][24] Randomized, cross-over (4-5w) 10 adults with familial hypercholesterolemia (2 of those had possibly FCH) (aged 50 ± 5 yrs old) Low-fat/low-cholesterol/high-protein (23%) diet vs low-fat/low-cholesterol/low-protein (11%) diet d, day; FCH, familial combined hyperlipidemia; FH, familial hypercholesterolemia; m, months; w, weeks; yrs, years.…”
Section: Study Characteristicsmentioning
confidence: 99%
See 2 more Smart Citations
“…[9,11,14,[16][17][18][19] Among the rest studies including adults with FH, in 8 RCTs the subjects were also treated with lipid-lowering drugs. [10,13,15,[20][21][22][23][24] Randomized, cross-over (4-5w) 10 adults with familial hypercholesterolemia (2 of those had possibly FCH) (aged 50 ± 5 yrs old) Low-fat/low-cholesterol/high-protein (23%) diet vs low-fat/low-cholesterol/low-protein (11%) diet d, day; FCH, familial combined hyperlipidemia; FH, familial hypercholesterolemia; m, months; w, weeks; yrs, years.…”
Section: Study Characteristicsmentioning
confidence: 99%
“…[21] • Three trials compared the effect of treatment with omega-3 fatty acids in comparison with placebo. [10,13,20] The daily supplementation of omega-3 fatty acids was 5.1 g with a ratio of eicosapentaenoic acid/ docosahexaenoic acid (EPA/DHA) of 1:1 in the oldest trial [10], whereas the treatment arm in the rest RCTs comprised of 4 gr/d of EPA/DHA (46% EPA and 38% DHA). [13,20].…”
Section: Study Characteristicsmentioning
confidence: 99%
See 1 more Smart Citation
“…Study subjects presented with a saturated fat challenge following chronic consumption of saturated fat experienced a more pronounced postprandial lipemia than subjects presented with an n-6PUFA challenge, following n-6PUFA chronic feeding or an omega-3 polyunsaturated fatty acid (n-3PUFA) challenge following n-3PUFA chronic feeding [ 51 ]. Chronic supplementation with long chain n-3PUFA has also been demonstrated to reduce postprandial lipemia in response to a fat challenge [ 52 , 53 ].…”
Section: Factors Modulating Postprandial Lipemiamentioning
confidence: 99%
“…Desde hace ya varias décadas se vienen utilizando numerosos productos de origen vegetal para prevenir eventos cardiovasculares con mayor o menor éxito. En el caso concreto de las dislipemias, los productos más utilizados son la levadura roja del arroz (Monascus purpureus) [6][7][8], los policosanoles de la caña de azúcar [9][10][11], los ácidos grasos omega-3 del pescado azul [12], la lecitina de soja y el ajo. Todos ellos han sido ampliamente utilizados de forma individual, combinados entre sí y también en combinación con fármacos.…”
Section: Introductionunclassified